Adagene (ADAG) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Adagene (ADAG) over the past year, gaining 1.5% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -98.2% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($133.6 million vs $118.2 million), about 1.1 times the size, while Adagene is growing revenue faster (+7332.8% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | ZNTL |
|---|---|---|
| Share price | $1.76 | $1.36 |
| Market cap | $118.17M | $133.64M |
| 1-day change | -12.44% | 0.00% |
| YTD return | -6.88% | +0.74% |
| 1-year return | -2.22% | +1.49% |
| 5-year return | -79.75% | -98.21% |
| EPS (TTM) | $-0.37 | $-1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | $0 |
| Revenue growth (YoY) | +7332.76% | -100.00% |
| Net income (latest FY) | $-17.61M | $-137.06M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $6.95 |
| 52-week low | $1.27 | $1.30 |
| Distance from 52-week high | -63.71% | -80.43% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +463.07% | +447.06% |
| Average volume | 348.81K | 1.26M |
| Shares outstanding | 67.14M | 98.27M |
| Employees | 128 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Adagene grew revenue faster in its latest fiscal year (+7332.76% vs -100.00%).
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
ADAG vs ZNTL FAQ
Which is bigger, Adagene or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $133.64M compared with $118.17M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or ZNTL?
ZNTL returned +1.49% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.